For patients with surgically resected melanoma of a primary tumor thickness of 4 mm or greater (T4 lesions) and/or regional lymph node metastases who are at increased risk of recurrence and death (stages IIB or greater), the only Federal Drug Administration (FDA) approved effective adjuvant therapy remains interferon-α (IFN-α). This evidence concerns the gene IFNA1 and melanoma.